What is the recommended treatment for shingles (herpes zoster) including antiviral therapy and pain management?

Shingles Treatment

For herpes zoster (shingles), start oral antiviral therapy with valacyclovir 1 gram three times daily, famciclovir 500 mg three times daily, or acyclovir 800 mg five times daily for 7 days, ideally within 72 hours of rash onset, combined with appropriate analgesics for pain control.

Antiviral Therapy

The cornerstone of shingles treatment is prompt antiviral therapy, which reduces disease severity, shortens the duration of the rash, and decreases acute pain intensity 1. Treatment should be initiated within 72 hours of rash onset for maximum benefit, though patients presenting later with new lesion formation or complications may still benefit 2.

First-Line Antiviral Options:

• Valacyclovir 1 gram orally three times daily for 7 days (preferred due to better bioavailability and less frequent dosing)
• Famciclovir 500 mg orally three times daily for 7 days (alternative with similar efficacy)
• Acyclovir 800 mg orally five times daily for 7 days (effective but requires more frequent dosing)

All three agents have demonstrated comparable efficacy in clinical practice 1, 2. Valacyclovir and famciclovir offer the advantage of less frequent dosing, which may improve adherence.

Special Situations:

Severe disease or complications (disseminated infection, CNS involvement, ophthalmic involvement):

• Acyclovir 10 mg/kg IV every 8 hours until clinical improvement, then transition to oral therapy 3

Immunocompromised patients (HIV, transplant recipients, cancer patients):

• Higher doses may be needed: acyclovir 800 mg five times daily or equivalent
• Consider IV therapy for severe cases
• Monitor for acyclovir-resistant strains if lesions persist despite treatment
• For proven resistance: foscarnet 40 mg/kg IV every 8 hours 3

Pain Management

Pain control is critical for quality of life and may help prevent postherpetic neuralgia (PHN), the most common and debilitating complication affecting approximately 20% of patients 1.

Acute Pain Management Algorithm:

Mild to moderate pain:

• Acetaminophen or NSAIDs as first-line
• Add gabapentin 300-900 mg three times daily or pregabalin 150-300 mg twice daily if inadequate response

Moderate to severe pain:

• Gabapentin or pregabalin as above
• Add short-acting opioids (oxycodone, hydrocodone) for breakthrough pain
• Consider tricyclic antidepressants (amitriptyline 25-75 mg at bedtime) for neuropathic component

Adjunctive measures:

• Cool compresses to affected areas
• Loose-fitting clothing to minimize irritation
• Keep lesions clean and dry to prevent secondary bacterial infection

Postherpetic Neuralgia Prevention and Treatment

Prevention: Early antiviral therapy with valacyclovir or famciclovir is the only proven measure to reduce PHN risk 2. There is conflicting evidence regarding corticosteroids, and they are not routinely recommended 4.

If PHN develops (pain persisting >90 days after rash):

First-line agents:

• Gabapentin 1800-3600 mg daily in divided doses
• Pregabalin 150-600 mg daily in divided doses
• Tricyclic antidepressants (amitriptyline 25-150 mg at bedtime)

Second-line agents:

• Lidocaine 5% patches applied to affected area
• Capsaicin 8% patch (applied by healthcare provider)
• Long-acting opioids or tramadol for refractory cases 4

Critical Pitfalls to Avoid

1. Delaying treatment beyond 72 hours - While benefit decreases after this window, patients with ongoing vesicle formation or complications should still receive antivirals 1

2. Underdosing in immunocompromised patients - These patients require higher doses and closer monitoring 3

3. Inadequate pain control - Aggressive pain management during acute phase may reduce PHN risk and significantly improves quality of life

4. Missing ophthalmic involvement - Hutchinson's sign (vesicles on tip of nose) indicates nasociliary nerve involvement and requires urgent ophthalmology consultation to prevent vision loss

5. Assuming all patients are immunocompetent - Screen for underlying immunosuppression in younger patients (<50 years) or those with severe/atypical presentations

Age-Specific Considerations

Patients ≥50 years: Higher risk for PHN; aggressive early treatment is essential 1

Immunocompromised patients: Require higher antiviral doses, longer treatment duration, and close monitoring for complications and treatment failure 3